Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

The FDA officials wrote that AI held the promise to “radically increase efficiency” in examining as many as 500,000 pages submitted for approval decisions. Advertising.

HHS Secretary Robert F. Kennedy Jr. asked the FDA "to review the latest data on mifepristone ," but experts say concerns about the abortion pill's safety are misguided.

The FDA wrote on its website: "Most people infected with Salmonella will begin to develop symptoms 12 to 72 hours after infection. The illness, salmonellosis, usually lasts four to seven days and ...

The FDA is expected to decide on treatments for multiple myeloma, NSCLC, melanoma, phenylketonuria, and 2 rare kidney diseases.

The FDA plans to “rapidly make available” rare disease drugs and make use of surrogate endpoints to get promising medicines to patients before they clear the traditional efficacy bar for authorization ...

Presented by Alliance for Pharmacy Compounding — The Food and Drug Administration commissioner has committed to reviewing the abortion drug mifepristone after previously stating he had no plans ...

“It is highly concerning that the FDA is committed to a new review of mifepristone, given the massive amount of evidence on its safety and efficacy,” said Dr. Angel Foster, co-founder of the ...

Food and Drug Administration (FDA) Commissioner Marty Makary committed to reviewing the abortion drug mifepristone in a letter sent to Sen. Josh Hawley (R-Mo.). “As with all drugs, FDA continues ...

A new Food and Drug Administration AI tool that could speed up reviews and approvals of medical devices such as pacemakers and insulin pumps is struggling with simple tasks, according to two ...